Stockreport

Palatin Technologies doses first subject in Phase II obesity treatment trial [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF Bremelanotide is a melanocortin 4 receptor (MC4R) while tirzepatide is a GLP-1/GIP receptor agonist. Dubbed BMT-801, the randomised, double-blind, placebo-controlled [Read more]